Oncology Biosimilars Market Research: Global Status & Forecast by Geography, Type & Application (2015-2025)
Region:Global
Product Code:99SGL228Lif20190500009105
June 2019
59
About the Report
According to 99Strategy, the Global Oncology Biosimilars Market is estimated to reach xxx million USD in 2019 and projected to grow at the CAGR of xx% during the 2020-2025. The report analyses the global Oncology Biosimilars market, the market size and growth, as well as the major market participants.
The analysis includes market size, upstream situation, market segmentation, market segmentation, price & cost and industry environment. In addition, the report outlines the factors driving industry growth and the description of market channels.The report begins from overview of industrial chain structure, and describes the upstream. Besides, the report analyses market size and forecast in different geographies, type and end-use segment, in addition, the report introduces market competition overview among the major companies and companies profiles, besides, market price and channel features are covered in the report.
Key Regions
Asia Pacific
North America
Europe
South America
Middle East & Africa
Key Companies
Celltrion Inc.
Pfizer Inc.
Biocon
BIOCAD
Apotex Inc.
Dr. Reddy's
Sandoz International GmbH
Intas Pharmaceuticals Ltd.
STADA Arzneimittel AG
Teva Pharmaceutical Industries Ltd
Key Product Type
G-CSF
Hematopoietic Agents
Monoclonal Antibodies
Market by Application
Retail Pharmacies
Hospital Pharmacies
Online Pharmacies
Main Aspects covered in the Report
Overview of the Oncology Biosimilars market including production, consumption, status & forecast and market growth
2015-2018 historical data and 2019-2025 market forecast
Geographical analysis including major countries
Overview the product type market including development
Overview the end-user market including development
Scope of the Report
Products
Table of Contents
Table of Content
1 Industrial Chain Overview
1.1 Oncology Biosimilars Industry
1.1.1 Overview
1.1.2 Characteristics of Oncology Biosimilars
1.2 Upstream
1.2.1 Major Materials
1.2.2 Manufacturing Overview
1.3 Product List By Type
1.3.1 G-CSF
1.3.2 Hematopoietic Agents
1.3.3 Monoclonal Antibodies
1.4 End-Use List
1.4.1 Demand in Retail Pharmacies
1.4.2 Demand in Hospital Pharmacies
1.4.3 Demand in Online Pharmacies
1.5 Global Market Overview
1.5.1 Global Market Size and Forecast, 2015-2025
1.5.2 Global Market Size and Forecast by Geography with CAGR, 2015-2025
1.5.3 Global Market Size and Forecast by Product Type with CAGR, 2015-2025
1.5.4 Global Market Size and Forecast by End-Use with CAGR, 2015-2025
2 Global Production & Consumption by Geography
2.1 Global Production & Consumption
2.1.1 Global Production
2.1.2 Global Consumption
2.2 Geographic Production & Consumption
2.2.1 Production
2.2.1.1 Asia-Pacific
2.2.1.2 North America
2.2.1.3 South America
2.2.1.4 Europe
2.2.1.5 Middle East & Africa
2.2.2 Consumption
2.2.2.1 Asia-Pacific
2.2.2.2 North America
2.2.2.3 South America
2.2.2.4 Europe
2.2.2.5 Middle East & Africa
3 Major Manufacturers Introduction
3.1 Manufacturers Overview
3.2 Manufacturers List
3.2.1 Celltrion Inc. Overview
3.2.1.1 Product Specifications
3.2.1.2 Business Data (Production Volume (Volume), Production Amount (Million USD), Price, Cost, Margin)
3.2.1.3 Recent Developments
3.2.1.4 Future Strategic Planning
3.2.2 Pfizer Inc. Overview
3.2.2.1 Product Specifications
3.2.2.2 Business Data (Production Volume (Volume), Production Amount (Million USD), Price, Cost, Margin)
3.2.2.3 Recent Developments
3.2.2.4 Future Strategic Planning
3.2.3 Biocon Overview
3.2.3.1 Product Specifications
3.2.3.2 Business Data (Production Volume (Volume), Production Amount (Million USD), Price, Cost, Margin)
3.2.3.3 Recent Developments
3.2.3.4 Future Strategic Planning
3.2.4 BIOCAD Overview
3.2.4.1 Product Specifications
3.2.4.2 Business Data (Production Volume (Volume), Production Amount (Million USD), Price, Cost, Margin)
3.2.4.3 Recent Developments
3.2.4.4 Future Strategic Planning
3.2.5 Apotex Inc. Overview
3.2.5.1 Product Specifications
3.2.5.2 Business Data (Production Volume (Volume), Production Amount (Million USD), Price, Cost, Margin)
3.2.5.3 Recent Developments
3.2.5.4 Future Strategic Planning
3.2.6 Dr. Reddy's Overview
3.2.6.1 Product Specifications
3.2.6.2 Business Data (Production Volume (Volume), Production Amount (Million USD), Price, Cost, Margin)
3.2.6.3 Recent Developments
3.2.6.4 Future Strategic Planning
3.2.7 Sandoz International GmbH Overview
3.2.7.1 Product Specifications
3.2.7.2 Business Data (Production Volume (Volume), Production Amount (Million USD), Price, Cost, Margin)
3.2.7.3 Recent Developments
3.2.7.4 Future Strategic Planning
3.2.8 Intas Pharmaceuticals Ltd. Overview
3.2.8.1 Product Specifications
3.2.8.2 Business Data (Production Volume (Volume), Production Amount (Million USD), Price, Cost, Margin)
3.2.8.3 Recent Developments
3.2.8.4 Future Strategic Planning
3.2.9 STADA Arzneimittel AG Overview
3.2.9.1 Product Specifications
3.2.9.2 Business Data (Production Volume (Volume), Production Amount (Million USD), Price, Cost, Margin)
3.2.9.3 Recent Developments
3.2.9.4 Future Strategic Planning
3.2.10 Teva Pharmaceutical Industries Ltd Overview
3.2.10.1 Product Specifications
3.2.10.2 Business Data (Production Volume (Volume), Production Amount (Million USD), Price, Cost, Margin)
3.2.10.3 Recent Developments
3.2.10.4 Future Strategic Planning
4 Market Competition Pattern
4.1 Market Size and Sketch
4.2 Company Market Share
4.2.1 Global Production by Major Manufacturers
4.2.2 Market Concentration Analysis
4.3 Market News and Trend
4.3.1 Merger & Acquisition
4.3.2 New Product Launch
5 Product Type Segment
5.1 Global Overview by Product Type Segment
5.2 Segment Subdivision by Product Type
5.2.1 Market in G-CSF
5.2.1.1 Market Size
5.2.1.2 Situation & Development
5.2.2 Market in Hematopoietic Agents
5.2.2.1 Market Size
5.2.2.2 Situation & Development
5.2.3 Market in Monoclonal Antibodies
5.2.3.1 Market Size
5.2.3.2 Situation & Development
6 End-Use Segment
6.1 Global Overview by End-Use Segment
6.2 Segment Subdivision
6.2.1 Market in Retail Pharmacies
6.2.1.1 Market Size
6.2.1.2 Situation & Development
6.2.2 Market in Hospital Pharmacies
6.2.2.1 Market Size
6.2.2.2 Situation & Development
6.2.3 Market in Online Pharmacies
6.2.3.1 Market Size
6.2.3.2 Situation & Development
7 Market Forecast & Trend
7.1 Regional Forecast
7.2 Consumption Forecast
7.2.1 Product Type Forecast
7.2.2 End-Use Forecast
7.3 Investment Trend
7.4 Consumption Trend
8 Price & Channel
8.1 Price and Cost
8.1.1 Price
8.1.2 Cost
8.2 Channel Segment
9 Market Drivers & Investment Environment
9.1 Market Drivers
9.2 Investment Environment
10 Research Conclusion
Research Methodology
Why Buy From Us?
What makes us stand out is that our consultants follows Robust, Refine and Result (RRR) methodology. i.e. Robust for clear definitions, approaches and sanity checking, Refine for differentiating respondents facts and opinions and Result for presenting data with story
We have set a benchmark in the industry by offering our clients with syndicated and customized market research reports featuring coverage of entire market as well as meticulous research and analyst insights.
While we don't replace traditional research, we flip the method upside down. Our dual approach of Top Bottom & Bottom Top ensures quality deliverable by not just verifying company fundamentals but also looking at the sector and macroeconomic factors.
With one step in the future, our research team constantly tries to show you the bigger picture. We help with some of the tough questions you may encounter along the way: How is the industry positioned? Best marketing channel? KPI's of competitors? By aligning every element, we help maximize success.
Our report gives you instant access to the answers and sources that other companies might choose to hide. We elaborate each steps of research methodology we have used and showcase you the sample size to earn your trust.
If you need any support, we are here! We pride ourselves on universe strength, data quality, and quick, friendly, and professional service.